Business Context and Reporting Period
The submitted filing is a Form 10-Q for Big Rock Partners Acquisition Corp., not NRX Pharmaceuticals, Inc. It covers the quarter and six months ended June 30, 2020, and was filed August 14, 2020. Big Rock was a Delaware blank-check company formed to identify and complete a business combination; it had not generated operating revenue and was still seeking a target.
Financial Results and Position
| Metric | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 |
|---|---|---|---|---|
| Operating expenses | $181,259 | $175,742 | $300,559 | $338,923 |
| Other income | $25,017 | $392,439 | $490,165 | $775,301 |
| Net income (loss) | $(149,501) | $176,021 | $123,719 | $363,986 |
| Basic and diluted earnings (loss) per share | $(0.06) | $(0.03) | $0.04 | $(0.06) |
- Six-month 2020 other income included $352,071 of forgiven debt and $138,094 of Trust Account interest. The debt forgiveness was a nonrecurring item.
- Cash used in operating activities was $306,891 for the six months ended June 30, 2020, compared with $478,343 in the prior-year period.
- Investing activities provided $25,903,054, primarily from $25,997,965 withdrawn from the Trust Account to fund stockholder redemptions. Financing activities used $25,596,162, principally for the same redemptions.
- At June 30, 2020, cash outside the Trust Account was $7. Trust Account assets were $6,240,245, including approximately $168,000 of interest income. Total assets were $6,277,048.
- Total liabilities were $2,650,805, including $1,668,091 of Extension Notes and $685,476 owed under a related-party promissory note. Stockholders’ equity was $3,626,243.
- The Company reported a working-capital deficit of $264,031, excluding $3,596 of prepaid income taxes funded from the Trust Account. It reported no long-term debt, lease obligations, or off-balance-sheet arrangements.
Material Changes Versus the Prior Comparable Period
- Second-quarter 2020 changed from net income of $176,021 to a net loss of $149,501, primarily because Trust Account interest fell from $392,439 to $25,017 while operating expenses were broadly stable.
- Six-month net income declined from $363,986 to $123,719. The 2020 result benefited from $352,071 of debt forgiveness, while prior-year results benefited from substantially higher Trust Account interest of $775,301.
- Trust Account assets declined from $32,005,205 at December 31, 2019 to $6,240,245 at June 30, 2020, largely because of $25,997,965 paid to redeeming stockholders.
- Shares subject to possible redemption declined from 2,305,335 at December 31, 2019 to none at June 30, 2020. Common shares outstanding, excluding redeemable shares, declined from 2,844,414 to 2,716,028.
- The Company withdrew approximately $120,830 of Trust Account interest during the first six months of 2020 to pay taxes; cumulative withdrawals for taxes were approximately $676,188.
Outlook, Risks, Contingencies, and Unusual Items
- On July 23, 2020, stockholders approved an extension of the business-combination deadline from July 23, 2020 to December 23, 2020. Approximately 27,786 shares were redeemed for about $299,253, or approximately $10.77 per share.
- If no business combination is completed by the extended deadline, the Company must cease operations, redeem the public shares using Trust Account proceeds, and wind up. Public rights and warrants may expire worthless, and the per-share liquidation value could be below $10.00.
- As of June 30, 2020, the Company had only $7 of operating cash and depended on loans from the Sponsor and Investor to fund operating and extension expenses. These parties were not generally obligated to provide additional funding beyond specified arrangements.
- Extension Notes and certain Sponsor loans would generally be forgiven if a business combination is not completed, subject to specified exceptions. Up to $200,000 of certain Sponsor-funded expenses may be repaid after a successful transaction if sufficient funds are available.
- COVID-19 could adversely affect the Company’s search for a target and financial position, but the specific impact was not determinable at the reporting date.
- The Company previously faced Nasdaq listing deficiencies related to the minimum number of public holders and conditions imposed by the Nasdaq Hearings Panel. On August 11, 2020, Nasdaq notified the Company that it had regained compliance and that the matter was closed.
- The Company disclosed no legal proceedings and no material changes to previously reported risk factors other than the risk that negative interest rates could reduce Trust Account value and the public-stockholder redemption amount.
Facts an Investor Should Verify
- Verify the filing identity: the supplied document is for Big Rock Partners Acquisition Corp. and does not identify NRX Pharmaceuticals, Inc.
- Confirm whether a business combination was completed by December 23, 2020 and review all subsequent filings for the transaction or liquidation outcome.
- Reconcile the post-June 30, 2020 Trust Account balance, redemptions, extension deposits, and per-share redemption value.
- Review the terms, maturity, forgiveness provisions, and related-party status of the $1,668,091 Extension Notes and $685,476 Sponsor-related note.
- Assess dilution from outstanding rights, warrants, Founder Shares, placement securities, and the underwriter’s unit purchase option.
- Confirm Nasdaq’s continued-listing status and any later changes to the Company’s securities or corporate identity.